ONE-WAYDated event · through FY2019

Discontinuation of BELVIQ Development for Obesity in Japan

An individual drug development program involving the discontinuation of BELVIQ development for obesity in Japan and recognition of an impairment loss on the related in-process research and development (IPR&D) asset.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2019 →Last written FY2019

Directionhurts0 helps · 1 hurts · 0 flat